INT242212

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.65
First Reported 2008
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 29
Total Number 29
Disease Relevance 11.36
Pain Relevance 1.52

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

small molecule metabolic process (GLP1R) plasma membrane (GLP1R) signal transducer activity (GLP1R)
Anatomy Link Frequency
plasma 3
endocrine cells 2
duodenum 2
liver 1
brain 1
GLP1R (Homo sapiens)
Pain Link Frequency Relevance Heat
agonist 229 100.00 Very High Very High Very High
adenocard 38 99.28 Very High Very High Very High
tolerance 12 95.44 Very High Very High Very High
abdominal pain 31 94.32 High High
Central nervous system 24 94.24 High High
potassium channel 28 93.64 High High
Spinal cord 1 48.12 Quite Low
Neuropeptide 59 47.36 Quite Low
Action potential 4 5.84 Low Low
ischemia 36 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Diabetes Mellitus 1327 99.72 Very High Very High Very High
Vomiting 148 98.36 Very High Very High Very High
Sprains And Strains 9 98.36 Very High Very High Very High
Impaired Glucose Tolerance 11 95.76 Very High Very High Very High
Diarrhoea 20 95.56 Very High Very High Very High
Hypoglycemia 231 95.08 Very High Very High Very High
Apoptosis 14 94.48 High High
Abdominal Pain 31 94.32 High High
Gastric Motility Disorder 3 91.92 High High
Obesity 120 90.88 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The GLP-1 receptor is expressed at the mRNA level and protein level in proximal tubular kidney cells [101].
Gene_expression (expressed) of GLP-1 receptor in kidney
1) Confidence 0.65 Published 2010 Journal Pediatr Nephrol Section Body Doc Link PMC2874027 Disease Relevance 0.67 Pain Relevance 0.08
An adenoviral vectored gene therapeutic option transfecting the GLP-1 gene into hepatozytes of a diabetic rat strain showed positive effects in one study, but because of the present difficulties and safety concerns using these methods in humans, this theoretical option has not been followed up so far [19].
Gene_expression (transfecting) of GLP-1 associated with diabetes mellitus and sprains and strains
2) Confidence 0.65 Published 2010 Journal Pediatr Nephrol Section Body Doc Link PMC2874027 Disease Relevance 0.58 Pain Relevance 0.13
Taspoglutide shows high binding affinity to the human GLP-1 receptor and assessment of its relative activity on cyclic adenosine monophosphate stimulation in cells expressing the GLP-1 receptor suggests that it is fully active [4].
Gene_expression (expressing) of GLP-1 receptor associated with adenocard
3) Confidence 0.59 Published 2010 Journal Diabetic Medicine Section Body Doc Link PMC2948428 Disease Relevance 0.25 Pain Relevance 0.10
Also, subcutaneous injections of GLP-1 do not lead to a sufficiently high and long-lasting elevation of GLP-1 concentrations to use native GLP-1 as a practical therapeutic agent.
Gene_expression (injections) of GLP-1
4) Confidence 0.57 Published 2010 Journal Pediatr Nephrol Section Body Doc Link PMC2874027 Disease Relevance 0.67 Pain Relevance 0.10
Fig. 1Multiple physiological effects of GLP-1 (adapted with permission from [6, 104])
Gene_expression (effects) of GLP-1
5) Confidence 0.57 Published 2010 Journal Pediatr Nephrol Section Body Doc Link PMC2874027 Disease Relevance 0.37 Pain Relevance 0.05
In the past decade, the pharmacological actions of the incretin hormone glucagon-like peptide-1 (GLP-1) were utilised to develop two novel substance classes for type 2 diabetes therapy: the GLP-1 receptor agonists (or “GLP-1 mimetics”) and the dipeptidyl-peptidase-IV inhibitors (DPP-4 inhibitors or “GLP-1 enhancers”) [6].
Gene_expression (mimetics) of GLP-1 associated with diabetes mellitus and agonist
6) Confidence 0.57 Published 2010 Journal Pediatr Nephrol Section Body Doc Link PMC2874027 Disease Relevance 0.37 Pain Relevance 0.05
Physiological actions of GLP-1
Gene_expression (actions) of GLP-1
7) Confidence 0.57 Published 2010 Journal Pediatr Nephrol Section Body Doc Link PMC2874027 Disease Relevance 0.40 Pain Relevance 0.04
In the past decade, the pharmacological actions of the incretin hormone glucagon-like peptide-1 (GLP-1) were utilised to develop two novel substance classes for type 2 diabetes therapy: the GLP-1 receptor agonists (or “GLP-1 mimetics”) and the dipeptidyl-peptidase-IV inhibitors (DPP-4 inhibitors or “GLP-1 enhancers”) [6].
Gene_expression (mimetics) of GLP-1 receptor associated with diabetes mellitus and agonist
8) Confidence 0.57 Published 2010 Journal Pediatr Nephrol Section Body Doc Link PMC2874027 Disease Relevance 0.38 Pain Relevance 0.05
Conversely, hyperglycaemia acutely reduces the postprandial levels of GIP and GLP-1, possibly through a deceleration of gastric emptying.
Gene_expression (levels) of GLP-1
9) Confidence 0.51 Published 2010 Journal Pediatr Nephrol Section Body Doc Link PMC2874027 Disease Relevance 0.45 Pain Relevance 0.05
GLP-1 is a product of the glucagon gene and is post-translationally cleaved from preproglucagon in the neuroendocrine L-cells of the intestinal mucosa and in the central nervous system.
Gene_expression (product) of GLP-1 in central nervous system associated with central nervous system
10) Confidence 0.49 Published 2010 Journal Pediatr Nephrol Section Body Doc Link PMC2874027 Disease Relevance 0.40 Pain Relevance 0.05
GLP-1 is a 30 amino acid polypeptide, which is produced by the intestinal L-cells localized mainly in the distal portion of the small intestine and in the large intestine.
Gene_expression (produced) of GLP-1 in large intestine
11) Confidence 0.48 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597770 Disease Relevance 0.33 Pain Relevance 0
Direct effects of GLP-1 on ?
Gene_expression (effects) of GLP-1
12) Confidence 0.42 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597770 Disease Relevance 0.23 Pain Relevance 0.13
DPP-4 inhibition increases not only prandial but also fasting levels of active GLP-1 and results in an overall increase in GLP-1 levels with maintenance of circadian rhythm throughout the day.
Gene_expression (levels) of GLP-1
13) Confidence 0.42 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597770 Disease Relevance 0.13 Pain Relevance 0
As a result of DPP-4 activity, intact, biologically active GLP-1 represents only 10% to 20% of total plasma GLP-1 (Deacon et al 1995).
Gene_expression (represents) of GLP-1 in plasma
14) Confidence 0.42 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597770 Disease Relevance 0.29 Pain Relevance 0
Patients with type 2 diabetes exhibit an attenuated insulinotropic action of GIP but not GLP-1 and a significant reduction in meal-stimulated levels of GLP-1 (Nauck et al 1993; Toft-Nielsen et al 2001).
Gene_expression (action) of GLP-1 associated with diabetes mellitus
15) Confidence 0.42 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597770 Disease Relevance 0.32 Pain Relevance 0.04
Through preventing the rapid degradation of incretin hormones, DPP-4 inhibitors result in postprandial increases in levels of biologically active intact GLP-1 and reduce glucose production from the liver by inhibition of glucagon from the ?
Gene_expression (levels) of GLP-1 in liver
16) Confidence 0.42 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597770 Disease Relevance 0.06 Pain Relevance 0
As a result of DPP-4 activity, intact, biologically active GLP-1 represents only 10% to 20% of total plasma GLP-1 (Deacon et al 1995).
Gene_expression (represents) of GLP-1 in plasma
17) Confidence 0.42 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597770 Disease Relevance 0.29 Pain Relevance 0
Moreover, GLP-1 suppresses glucagon secretion in a glucose-dependent manner and is not thought to impair the glucagon counter-regulatory response to hypoglycemia (Nauck et al 2002).
Gene_expression (suppresses) of GLP-1 associated with hypoglycemia
18) Confidence 0.42 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597770 Disease Relevance 0.32 Pain Relevance 0.03
DPP-4 inhibition increases not only prandial but also fasting levels of active GLP-1 and results in an overall increase in GLP-1 levels with maintenance of circadian rhythm throughout the day.
Gene_expression (levels) of GLP-1
19) Confidence 0.42 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597770 Disease Relevance 0.12 Pain Relevance 0
Both GIP and GLP-1 receptors are expressed in various tissues.
Gene_expression (expressed) of GLP-1
20) Confidence 0.42 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597770 Disease Relevance 0.08 Pain Relevance 0.18

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox